Editas Medicine Inc. | Mutual Funds
Mutual Funds that own Editas Medicine Inc.
American Funds Small Cap World Fund
2,184,000
4.58%
0
0.19%
06/30/2018
SPDR S&P Biotech ETF
1,871,535
3.93%
4,815
1.05%
09/06/2018
ARK Innovation ETF
1,415,694
2.97%
0
3.29%
09/05/2018
Vanguard Small Cap Index Fund
1,069,843
2.24%
15,771
0.04%
07/31/2018
Vanguard Total Stock Market Index Fund
1,067,307
2.24%
0
0.01%
07/31/2018
iShares Russell 2000 ETF
955,323
2%
-510
0.07%
09/06/2018
Vanguard Small Cap Growth Index Fund
608,643
1.28%
8,415
0.08%
07/31/2018
ARK Genomic Revolution Multi Sector ETF
580,853
1.22%
3,243
6.19%
09/05/2018
Fidelity Blue Chip Growth Fund
548,423
1.14%
0
0.07%
07/31/2018
iShares Nasdaq Biotechnology ETF
547,560
1.14%
-7,161
0.18%
09/06/2018
| Address |
11 Hurley Street
Cambridge Massachusetts 02142
United States
|
|
Employees
|
- |
| Website |
http://www.editasmedicine.com |
| Updated |
07/08/2019 |
| Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. |
